Sandoz International GmbH
www.sandoz.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sandoz International GmbH
Second European Stelara Biosimilar Pits Sandoz Against Stada
Just days after the first European ustekinumab biosimilar launch, Sandoz has entered the fray with the second rival to Stelara, introducing its Samsung Bioepis-partnered Pyzchiva version to compete with Stada and Alvotech’s Uzpruvo.
Stock Watch: Investor Reactions Diverge As J&J And Novartis Report Q2 Results
Both of the first two companies to report second-quarter financials maintained full-year sales guidance. But while Johnson & Johnson’s investors seemed cheered, Novartis’s may have been concerned about familiar issues.
Sandoz And Just-Evotec Expand Biosimilars Collaboration
Just-Evotec Biologics has announced an expansion of its partnership with Sandoz to develop and manufacture biosimilars.
More Stelara Biosimilars Line Up For Launch In US And EU
Samsung Bioepis and partner Sandoz have won approval for a third US Stelara biosimilar. Meanwhile, in Europe Celltrion has become the latest firm to qualify for an ustekinumab marketing authorization.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice